AstraZenca: 100% Upside Based on Comps and Reasonable Valuation

This is a foreign company with a large market cap and ADR, but surprisingly little sell side coverage. We used super conservative estimates and concluded there is a 40% upside. Based on P/E of 6, EV/EBITDA of 3.7 and a large dividend yield, low debt load, we see a very strong compelling value play here….

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here